Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial

By: Silvia Marsoni · Clara Montagut · Filippo Pietrantonio · Andrea Sartore-Bianchi · Luca Lazzari · Francesca Bergamo · Maria Giulia Zampino · Noelia Tarazona · Mario Mandalà · Stefano Tamberi · Elena Elez · Cristina Santos Vivas · Paolo Luraghi · Michele Prisciandaro · Federica Tosi · Davide Ciardiello · Joana Vidal · Victor Seguì · Michele Palazzo · Giulia Maddalena · Katia Bencardino · Ida Taglialatela · Marta Guix · Eliana Rulli · Valentina Vettore · Federica Morano · Claudio Isella · Giovanni Crisafulli · Giorgio Patelli · Enzo Medico · Alberto Bardelli · Andrés Cervantes · Valter Torri · Josep Tabernero · Salvatore Siena · Sara Lonardi

14 September 2026 at 08:00

Nature Cancer, Published online: 14 September 2026; doi:10.1038/s43018-026-01237-9

Marsoni et al. evaluated the feasibility of a dynamic circulating tumor DNA-guided adjuvant and postadjuvant treatment strategy in patients with resected microsatellite-stable, high-risk stage II or III colon cancer in the phase 2 PEGASUS trial.

Reading view